Liq­uidia and Unit­ed Ther­a­peu­tics could bring new lung in­di­ca­tion in­to le­gal saga

Liq­uidia said in an SEC fil­ing Wednes­day that it will “ag­gres­sive­ly de­fend” against a po­ten­tial new patent cov­er­ing Unit­ed Ther­a­peu­tics’ tre­pros­tinil for the treat­ment of pul­monary hy­per­ten­sion as­so­ci­at­ed with in­ter­sti­tial lung dis­ease (PH-ILD).

The drug has been at the cen­ter of an on­go­ing court bat­tle be­tween the two com­pa­nies. On Wednes­day, Liq­uidia an­nounced in an SEC fil­ing that Unit­ed Ther­a­peu­tics re­ceived a no­tice of al­lowance re­gard­ing its patent ap­pli­ca­tion gen­er­al­ly cov­er­ing the treat­ment of PH-ILD us­ing an in­haled ver­sion of tre­pros­tinil, mean­ing the US Patent and Trade­mark of­fice has de­ter­mined Unit­ed is en­ti­tled to the patent.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER